Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Cell Biol Int
; 33(2): 239-46, 2009 Feb.
Article
in En
| MEDLINE
| ID: mdl-19103299
ABSTRACT
Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Apoptosis
/
Proto-Oncogene Proteins c-bcl-2
/
Taxoids
/
Diphosphonates
/
Imidazoles
/
Antineoplastic Agents
Limits:
Humans
/
Male
Language:
En
Journal:
Cell Biol Int
Year:
2009
Document type:
Article
Affiliation country:
Turkey